Population-based study suggests an increased risk of Alzheimer’sdisease in Sjögren’s syndrome

[1]  C. Pisoni,et al.  Role of M3 Muscarinic Acethylcholine Receptor Antibodies as a New Marker in Primary Sjögren Syndrome , 2017 .

[2]  M. Rischmueller,et al.  Primary Sjögren's syndrome. , 2016, Best practice & research. Clinical rheumatology.

[3]  F. LaFerla,et al.  AF710B, a Novel M1/σ1 Agonist with Therapeutic Efficacy in Animal Models of Alzheimer's Disease , 2015, Neurodegenerative Diseases.

[4]  H. Chiou,et al.  Alzheimer disease and risk of stroke , 2013, Neurology.

[5]  Taiji Ito,et al.  Prevalence of Sjögren's syndrome with dementia in a memory clinic , 2012, Journal of Neurological Sciences.

[6]  Y. Tavil,et al.  Atrial electromechanical delay and diastolic dysfunction in primary Sjögren syndrome. , 2012, Clinical and investigative medicine. Medecine clinique et experimentale.

[7]  Shih-Yi Lin,et al.  Risks, Subtypes, and Hospitalization Costs of Stroke Among Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study in Taiwan , 2012, The Journal of Rheumatology.

[8]  K. Tsai,et al.  Population based study on patients with traumatic brain injury suggests increased risk of dementia , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[9]  J. Sundquist,et al.  Risk of subsequent ischemic and hemorrhagic stroke in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden , 2012, BMC Neurology.

[10]  R. Jonsson,et al.  Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren's syndrome , 2011, Annals of the rheumatic diseases.

[11]  J. Britton,et al.  Autoimmune dementia: clinical course and predictors of immunotherapy response. , 2010, Mayo Clinic proceedings.

[12]  Nick C Fox,et al.  The diagnosis of young-onset dementia , 2010, The Lancet Neurology.

[13]  B. Mueller,et al.  Disruption of brain white matter microstructure in primary Sjögren's syndrome: evidence from diffusion tensor imaging. , 2010, Rheumatology.

[14]  M. Ramos-Casals,et al.  Cardiovascular risk factors in primary Sjögren's syndrome: a case-control study in 624 patients , 2010, Lupus.

[15]  V. Lennon,et al.  IMMUNOTHERAPY-RESPONSIVE DEMENTIAS AND ENCEPHALOPATHIES , 2010, Continuum.

[16]  V. Guern,et al.  Cognitive function and 99mTc-ECD brain SPECT are significantly correlated in patients with primary Sjögren syndrome: a case–control study , 2009, Annals of the rheumatic diseases.

[17]  O. J. Greve,et al.  Neuropsychiatric syndromes in patients with systemic lupus erythematosus and primary Sjögren syndrome: a comparative population-based study , 2008, Annals of the rheumatic diseases.

[18]  A. Tzioufas,et al.  Neuroendocrine Dysfunction in Sjögren’s Syndrome , 2008, Neuroimmunomodulation.

[19]  Chien-Jen Chen,et al.  Midlife risk factors for subtypes of dementia: a nested case-control study in Taiwan. , 2007, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[20]  E. Ros,et al.  High prevalence of serum metabolic alterations in primary Sjögren's syndrome: influence on clinical and immunological expression. , 2007, The Journal of rheumatology.

[21]  H. Moutsopoulos,et al.  Hypothalamic‐Pituitary‐Adrenal Axis Function in Sjögren's Syndrome , 2006, Annals of the New York Academy of Sciences.

[22]  D. Isenberg,et al.  Incidence of cancer in a cohort of patients with primary Sjogren's syndrome. , 2006, Rheumatology.

[23]  S. Rubin,et al.  Inflammatory markers and cognition in well-functioning African-American and white elders , 2003, Neurology.

[24]  R. Jonsson,et al.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group , 2002, Annals of the rheumatic diseases.

[25]  A. Berra,et al.  Muscarinic acetylcholine receptor antibodies as a new marker of dry eye Sjögren syndrome. , 2001, Investigative ophthalmology & visual science.

[26]  D. Isenberg,et al.  Autoantibody repertoire to Ro/SSA and La/SSB antigens in patients with primary and secondary Sjögren's syndrome. , 1996, Journal of autoimmunity.

[27]  S. Pillemer,et al.  Anti-salivary antibodies in primary Sjögren's syndrome. , 1995, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[28]  D. Gurwitz,et al.  NGF-dependent neurotrophic-like effects of AF102B, an M1 muscarinic agonist, in PC12M1 cells. , 1995, Neuroreport.

[29]  N. Kawashima,et al.  Primary Sjögren's syndrome with subcortical dementia. , 1993, Internal medicine.

[30]  F. Arnett,et al.  Sjögren's syndrome: association of anti-Ro(SS-A) antibodies with vasculitis, hematologic abnormalities, and serologic hyperreactivity. , 1983, Annals of internal medicine.

[31]  F. LaFerla,et al.  AF 710 B , a Novel M 1 / σ 1 Agonist with Therapeutic Efficacy in Animal Models of Alzheimer ’ s Disease , 2015 .

[32]  H. Soininen,et al.  Midlife rheumatoid arthritis increases the risk of cognitive impairment two decades later: a population-based study. , 2012, Journal of Alzheimer's disease : JAD.

[33]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[34]  A. Fisher,et al.  M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer’s disease , 2007, Journal of Molecular Neuroscience.

[35]  A. Fisher,et al.  AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease. , 2002, Journal of molecular neuroscience : MN.